| Similar Articles |
|---|
 |
The Motley Fool
August 3, 2007
Brian Lawler |
Vanda Announces Some Late-Stage Maneuvers Vanda Pharmaceuticals gets ready for a busy remainder of 2007. Management awaits approval on three different compounds in the near future. Investors should be prepared for a potentially volatile road ahead.   |
The Motley Fool
September 27, 2007
Brian Lawler |
A Step in a Winding Road for Vanda Vanda Pharmaceuticals has submitted a new drug application to the FDA for its lead drug, iloperidone, emphasizing a new approach to reduce safety issues. Investors, take note. |
The Motley Fool
December 7, 2006
Billy Fisher |
Breakout at Vanda Good news on the company's schizophrenia drug sends its shares skyrocketing. |
The Motley Fool
November 12, 2007
Brian Lawler |
Vanda Gets Set for a Busy 2008 Although it has no marketed products, Vanda Pharmaceuticals third-quarter reports set the stage for an exciting 2008. Investors. take note. |
The Motley Fool
June 27, 2008
Brian Lawler |
Vanda's Drug Draws a Yawn Shares of Vanda Pharmaceuticals have fallen more than 20% recently, even though the company said that its phase 3 clinical trial met its primary goal. |
The Motley Fool
August 1, 2007
Brian Lawler |
A Closer Look at Vanda Vanda Pharmaceuticals is a development stage drug maker worth keeping an eye on. Later this year Vanda plans to submit a New Drug Application to the FDA for its anti-psychotic medication, iloperidone. |
The Motley Fool
May 18, 2009
Brian Orelli |
Is There Life After 600% Returns? Just because a drug company gets a massive increase in the stock price after a positive clinical trial or an FDA approval, that doesn't mean all the growth is completely factored into the stock price. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
November 17, 2006
Billy Fisher |
Vanda Shareholders Sleeping Better The latest news on the company's insomnia drug boosts the stock. |
The Motley Fool
August 8, 2007
Brian Lawler |
Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline. |
The Motley Fool
May 19, 2009
Brian Orelli |
Flip-Flopping: Not Just for Politicians Anymore The FDA's change is good for companies. |
The Motley Fool
November 4, 2011
Brian Orelli |
You Should Have Seen These Biotech Failures Coming Micro cap biotechs are a value for a reason. |
The Motley Fool
August 27, 2008
Brian Orelli |
Another FDA Setback for Johnson & Johnson The company has to wait for an approval of its extended-release schizophrenia drug. Investors, take note. |
The Motley Fool
December 22, 2009
Brian Orelli |
2009 Biotech Cheers and Jeers Lessons from biotech's 2009 surprises. Will 2010 be just as exciting? Considering that it's biotech, I'd have to say "yes." |
The Motley Fool
May 31, 2007
Brian Lawler |
Dueling Fools: Eli Lilly Bear Well-managed companies don't always make for good investments. This pharmaceutical powerhouse is a good example. |
The Motley Fool
July 21, 2011
Brian Orelli |
Keep an Eye on Biotech Partners' Earnings Novartis' earnings are important for small biotechs Momenta and Vanda. |
The Motley Fool
November 26, 2007
Brian Lawler |
Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year. |
The Motley Fool
February 29, 2008
Brian Lawler |
FDA Floors Eli Lilly Eli Lilly receives an especially harsh rebuke from the FDA about one of its top candidates when the agency refused to approve a long-lasting injection version of its multibillion-dollar Zyprexa for schizophrenia and bipolar disorder. |
The Motley Fool
January 28, 2010
Brian Orelli |
The Biggest Development-Stage Drugmaker, Ever Eli Lilly seems to have a lot more in common with its development-stage little brothers than it does with its big pharma brethren. |
The Motley Fool
August 17, 2010
Travers & Jayson |
Interested in Cephalon ? Start Here! Every biotech company wants to discover the cure for cancer, Alzheimer's, or Wii knee. Every biotech investor hopes to catch the next Valeant Pharmaceuticals. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
January 22, 2008
Brian Lawler |
Seattle Genetics' Fortuitous Timing The drugmaker raises some much-needed cash with a $90 million stock offering. |
The Motley Fool
July 20, 2009
Brian Orelli |
Overnight Triple! Yee-Haw! The joys of owning biotech companies. The latest beneficiary, Human Genome Sciences, is up more than 220% today because Benlysta, their new drug for lupus, works. |
The Motley Fool
May 26, 2009
Brian Orelli |
Buy Now! It Might Get Bought! Clinical trial results and FDA approvals ultimately drive any increase in drugmakers' value. That's what pharmaceutical investors should focus on. The potential for an acquisition should be nothing more than icing on the cake. |
The Motley Fool
December 12, 2006
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Gallaher Group... Kyphon... Vanda Pharmaceuticals... Bank of New York... Pfizer... |
The Motley Fool
July 22, 2011
Anand Chokkavelu |
9 Small Biotechs Near 52-Week Lows Here are nine companies in this space that are within 20% of their 52-week lows and have market caps between roughly $200 million and $500 million. |
